Khabiri M, Nikouee A, Cwiklik L, Grissmer S, Ettrich R.  2011.  Charybdotoxin unbinding from the mKv1.3 potassium channel: A combined computational and experimental Study.  Journal of Physical Chemistry 115(39):11490-11500.

Prütting S, Grissmer S.  2011.  A novel current pathway parallel to the central pore in a mutant voltage-gated potassium channel.  Journal of Biological Chemistry286:20031-20042.

Schmid SI, Grissmer S.  2011.  Effect of verapamil on the action of methanethiosulfonate reagents on voltage-gated hKv1.3 channels: implications for the C-type inactivated state.  British Journal of Pharmacology 163(3):662-674.

Rossokhin A, Dreker T, Grissmer S, Zhorov B.  2011.  Why does the inner-helix mutation A413C double the stoichiometry of the Kv1.3 channel block by emopamil but not by verapamil.  Molecular Pharmacology 79(4):681-691.

Svoboda N, Prütting S, Grissmer S, Kerschbaum HH.  2009.  cAMP-dependent chloride conductances evokes ammonia-induced blebbing in the microglial cell line, BV-2. Cellular Physiology and Biochemistry 24(1-2):53-64.

Pegorano S, Lang M, Dreker T, Kraus J, Hamm S, Meere C, Feurle J, Tasler S, Prütting S, Kuras Z, Visan V, Grissmer S.  2009.  Inhibitors of potassium channels Kv1.3 and IK-1 as immunosuppressants.  Bioorganic and Medicinal Chemistry Letters 19(8):2299-2304.

Kuras Z, Grissmer S.  2009.  Effect of K⁺ and Rb⁺ on the action of verapamil on a voltage-gated K channel, hKv1.3: implications for a second open state?  British Journal of Pharmacology 157(5):757-768.

Grissmer S.  2008.  SK-Ca3 Small Conductance Calcium Activated Potassium Channels.  xPharm: The Comprehensive Pharmacology Reference, Pages 1-12.

Grissmer S.  2008.  SK-Ca2 Small Conductance Calcium Activated Potassium Channels.  xPharm: The Comprehensive Pharmacology Reference, Pages 1-7.

Grissmer S.  2008.  SK-Ca1 Small Conductance Calcium Activated Potassium Channels.  xPharm: The Comprehensive Pharmacology Reference, Pages 1-7.

Grissmer S.  2008.  IK-Ca Intermediate Conductance Calcium Activated Potassium Channels. xPharm: The Comprehensive Pharmacology Reference, Pages 1-9.

Grissmer S.  2008.  Calcium-Sensitive Potassium Channels.  xPharm: The Comprehensive Pharmacology Reference, Pages 1-4.

Küppers E, Gleiser C, Brito V, Wachter B, Pauly T, Hirt B, Grissmer S.  2008.  AQP4 expression in striatal primary cultures is regulated by dopamine - implications for proliferation of astrocytes. European Journal of Neuroscience 28:2173-2182.

Murthy SR, Teodorescu G, Nijholt IM, Dolga AM, Grissmer S, Spiess J, Blank T.  2008.  Identification and Characterization of a Novel, Shorter Isoform of the Small Conductance Ca(2+)- Activated K(+) Channel SK2.  Journal of Neurochemistry106(6):2312-2321.

Zierler S, Frei E, Grissmer S, Kerschbaum HH.  2008.  Chloride influx provokes lamellipodium formation in microglial cells.  Cellular Physiology and Biochemistry21(1-3):55-62.

Pimentel C, M'barek S, Visan V, Grissmer S, Sampieri F, Sabatier JM, Darbon H, Fajloun Z.  2008.  Chemical synthesis and 1H-NMR 3D structure determination of AgTx2-MTX chimera, a new potential blocker for Kv1.2 channel, derived from MTX and AgTx2 scorpion toxins.  Protein Science 17(1):107-118.

Liebau S, Vaida B, Grissmer S, Storch A, Böckers T, Dietl P, Wittekindt OH.  2007.  Formation of cellular projections in neural progenitor cells depends on SK3 channel activity.  Journal of Neurochemistry 101:1338-1350.

Frei E, Spindler I, Grissmer S, Jäger H.  2006.  Interaction of N-terminal and C-terminal parts of the small conductance Ca²⁺ activated K⁺ channels, hSK3.  Cellular Physiology and Biochemistry 18(4-5):165-176.

Liebau S, Pröpper C, Böckers T, Lehmann-Horn F, Storch A, Grissmer S, Wittekindt OH.  2006.  Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation.  Journal of Neurochemistry 99(2):426-437.

Rossokhin A, Teodorescu GA, Grissmer S, Zhorov B.  2006.  Interaction of d-tubocurarine with potassium channels:  Molecular modeling and ligand binding.  Molecular Pharmacology 69(4):1356-1365.

Mouhat S, Teodorescu G, Homerick D, Visan V, Wulff H, Wu Y, Grissmer S, Darbon H, De Waard M, Sabatier JM.  2006.  Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogues with a trimmed N-terminal domain.  Molecular Pharmacology 69(1):354-362

Wittekindt OH, Schmitz A, Lehmann-Horn F, Hänsel W, Grissmer S.  2006.  The human Ca²⁺-activated K⁺ channel, IK, can be blocked by the tricyclic antihistamine promethazine.  Neuropharmacology 50(4):458-467.

Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stuhmer W, Wang X.  2005.  International Union of Pharmacology. LIII. Nomenclature and Molecular Relationships of Voltage-Gated Potassium Channels.  Pharmacological Reviews 57(4):473-508.

Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H.  2005.  International Union of Pharmacology. LII. Nomenclature and Molecular Relationships of Calcium-Activated Potassium Channels.  Pharmacological Reviews 57(4):463-472.

Dreker T, Grissmer S.  2005.  Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state.  Molecular Pharmacology68(4):966-973.

M'Barek S, Chagot B, Andreotti N, Visan V, Mansuelle P, Grissmer S, Marrakchi M, El Ayeb M, Sampieri F, Darbon H, Fajloun Z, De Waard M, Sabatier JM.  2005.  Increasing the molecular contacts between maurotoxin and Kv1.2 channel augments ligand affinity.  Proteins 60(3):401-411.

Mouhat S, Visan V, Ananthakrishnan S, Wulff H, Andreotti N, Grissmer S, Darbon H, De Waard M, Sabatier JM.  2005.  K⁺ channel types targeted by synthetic OSK1, a potent toxin from Orthochirus scrobiculosis scorpion venom.  Biochemical Journal 385(Pt 1):95-104.

Visan V, Fajloun Z, Sabatier JM, Grissmer S.  2004.  Mapping of maurotoxin binding sites on hKv1.2, hKv1.3 and hIKCa1 channels.  Molecular Pharmacology 66:1103-1112.

Visan V, Sabatier JM, Grissmer S.  2004.  Block of maurotoxin and charybdotoxin on human intermediate-conductance calcium-activated potassium channels (hIKCa1).  Toxicon 43:973-980.

Jäger H, Grissmer S.  2004.  Characterization of the outer pore region of the apamin-sensitive Ca²⁺-activated K⁺ channel, rSK2.  Toxicon 43:951-960.

Grissmer S, Tytgat J.  2004.  Toxins and potassium channels.  Toxicon 43:863.

Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, Chandy KG.  2004.  Kv1.3-Blocking 5-Phenylalkoxypsoralens:  A New Class of Immunomodulators. Molecular Pharmacology 65:1364-1374.

Wittekindt OH, Visan V, Tomita H, Amhad F, Gargus JJ, Lehmann-Horn F, Grissmer S, Morris-Rosendahl D.  2004.  An apamin- and scyllatoxin-insensitve isoform of the human SK3 channel.  Molecular Pharmacology 65:788-801.

Jäger H, Dreker T, Buck A,  Giehl K, Gress T, Grissmer S.  2004.  Blockade of Ca²⁺-activated K⁺ channels, IK, inhibits human pancreatic cancer cell growth in vitro. Molecular Pharmacology 65:630-638.

Wittekindt OH, Dreker T, Morris-Rosendahl DJ, Lehmann-Horn F, Grissmer S.  2004.  A novel non-neuronal hSK3 isoform with a dominant-negative effect on hSK3 currents.  Cellular Physiology and Biochemistry 14(1-2):23-30.

Jouirou B, Mosbah A, Visan V, Grissmer S, M’Barek S, Fajloun Z, Van Rietschoten J, Rochat H, Lippens G, El Ayeb M, De Waard M, Mabrouk K, Sabatier JM.  2004.  Cobatoxin 1 from Centruroides noxius scorpion venom:  Chemical synthesis, 3-D structure in solution, pharmacology and docking on K⁺ channels. Biochemical Journal 377(Pt 1):37-49.

Mouhat S, Mosbah A, Visan V, Wulff H, Delepierre M, Darbon H, Grissmer S, De Waard M, Sabatier JM.  2004.  The "functional" dyad of scorpion toxin Pi1 is not per se a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Biochemical Journal 377(Pt 1):25-36.

Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, Kuperschmidt S, Kurachi Y, Lazdunski M, Lesage F, Lester HA, McKinnon D, Nichols CG, O'Kelly I, Robbins J, Robertson GA, Rudy B, Sanguinetti M, Seino S, Stuehmer W, Tamkun MM, Vandenberg CA, Wei A, Wulff H, Wymore RS.  2003.  International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels.  Pharmacolocal Reviews 55(4):583-586.

M’Barek S, Lopez-Gonzales I, Andreotti N, di Luccio E, Visan V, Grissmer S, Mosbah A, Judge S, El Ayeb M, Darbon H, Rochat H, Beraud E, Fajloun Z, De Waard M, Sabatier JM.  2003.  A Maurotoxin with constrained standard disulfide bridging – Innovative strategy of chemical synthesis, pharmacology and docking on K⁺ channels.  Journal of Biological Chemistry 278(33):31095-31104.

Bräuer M, Frei E, Claes L, Grissmer S, Jäger H.  2003.  Influence of the K/Cl cotransporter activity on the activation of volume-sensitive Cl^- channels in human osteoblasts.  American Journal of Physiology 285(1):C22-30.

Gilquin B, Racape J, Wrisch A, Visan V, Lecoq A, Grissmer S, Menez A, Gasparini S.  2002.  Structure of the BgK-Kv1.1 complex based on distance restrainst identified by double mutant cycles. Molecular basis for convergent evolution of Kv1 channel blockers.  Journal of Biological Chemistry 277:37406-37413.

Kerschbaum HH, Grissmer S, Engel E, Richter K, Lehner C, Jäger H.  2002.  A Shaker homologue encodes an A type current in Xenopus laevis.  Brain Research 927(1):55-68.

Jäger H, Grissmer S.  2001.  Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH.  FEBS Letters 488(1-2):45-50.

Röbe R, Grissmer S.  2000.  Block of the lymphocyte K⁺ channel mKv1.3 by the phenylalkylamine verapamil: kinetic aspects of block and disruption of accumulation of block by a single pointy mutation. British Journal of Pharmacology 131(7):1275-1284.

Wrisch A, Grissmer S.  2000.  Structural differences of bacterial and mammalian K⁺ channels. Journal of Biological Chemistry 275(50):39345-39352.

Weskamp M, Seidl W, Grissmer S.  2000.  Activation of Ca²⁺-activated K⁺ channels during hypotonic shock in human osteoblasts.  Journal of Membrane Biology 178(1):11-20.

Wulff H, Miller M, Hänsel W, Grissmer S, Cahalan MD, Chandy KG.  2000.  Design of a potent and selective inhibitor of the intermediate conductance Ca²⁺-activated K⁺ channel, IKCa1: a potential immunosuppressant.  Proceedings of the National Academy of Sciences, USA 97:8151-8156.

Jäger H, Adelman JP, Grissmer S.  2000.  SK2 encodes the apamin-sensitive Ca²⁺-activated K⁺ channels in the human leukemic T cell line, Jurkat. FEBS Letters 469(2-3):196-202.

Siemer C, Bushfield M, Newgreen D, Grissmer S.  2000.  Effects of NS1608 on MaxiK channels in smooth muscle cells from urinary bladder.  Journal of Membrane Biology 173(1):57-66.

Rauer H, Grissmer S.  1999.  The effect of deep pore mutations on the action of phenylalkylamines on the Kv1.3 potassium channel.  British Journal of Pharmacology127:1065-1074.

Bretschneider F, Wrisch A, Lehmann-Horn F, Grissmer S.  1999.  Expression in mammalian cells and electrophysiological characterization of two mutant Kv1.1 channels causing episodic ataxia type 1.  European Journal of Neuroscience 11(7):2403-2412.

Hanson DC, Nguyen AN, Mather RJ, Rauer H, Koch K, Burgess LE, Rizzi JP, Donovan CB, Bruns MJ, Canniff PC, Cunningham AC, Verdries KA, Mena E, Kath JC, Gutman GA, Cahalan MD, Grissmer S, Chandy KG.  1999.  UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation.  British Journal of Pharmacology126:1707-1716.

Bretschneider F, Wrisch A, Lehmann-Horn F, Grissmer S.  1999.  External tetraethylammonium (TEA⁺) as a molecular caliper for sensing the shape of the outer vestibule of potassium channels.  Biophysical Journal 76(5):2351-2360.

Siemer C, Grissmer S.  1999.  MaxiK channels: molecular structure, function, and tissue distribution. Perspectives in drug discovery and design:  Animal toxins and potassium channels 15/16:155-165.

Kalman K, Pennington M, Lanigan MD, Nguyen AN, Rauer H, Mahnir V, Paschetto K, Kem WR, Grissmer S, Gutman GA, Christian E, Cahalan MD, Norton R, Chandy KG.  1998.  ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.  Journal of Biological Chemistry 273(49):32697-32707.

Wulff H, Rauer H, Düring T, Hanselmann C, Ruff K, Wrisch A, Grissmer S, Hänsel W.  1998.  Alkoxypsoralens - Novel nonpeptide blockers of Shaker-type K⁺ channels: synthesis and photoreactivity.  Journal of Medicinal Chemistry 41(23):4542-4549.

Jäger H, Rauer H, Nguyen AN, Aiyar J, Chandy KG, Grissmer S.  1998.  Regulation of mammalian Shaker-related K⁺ channels: evidence for non-conducting closed and non-conducting inactivated states.  Journal of Physiology 506.2:291-301.

Grissmer S.  1997.  Potassium channels still hot.  Trends in Pharmacological Sciences 18:347-350.

Jäger H, Grissmer S.  1997.  Small Ca²⁺-activated potassium channels in human leukemic T cells and activated human peripheral blood T lymphocytes. Cellular Physiology and Biochemistry 7(3):179-187.

Steinert M, Grissmer S.  1997.  Novel activation stimulus of chloride channels by potassium in human osteoblasts and human leukemic T lymphocytes.  Journal of Physiology 500.3:653-660.

Nguyen A, Kath J, Hanson DC, Biggers MS, Kaniff PC, Donovan C, Mather RJ, Bruns M, Dethlefs B, Rauer H, Aiyar J, Lepple-Wienhues A, Gutman GA, Grissmer S, Cahalan MD, Chandy KG.  1996.  Novel non-peptide agents block the C-type inactivated conformation of Kv1.3, and suppress T-cell activation.  Molecular Pharmacology 50:1672-1679.

Rauer H, Grissmer S.  1996.  Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3.  Molecular Pharmacology 50:1625-1634.

Hanselmann C, Grissmer S.  1996.  Characterization of apamin-sensitive Ca²⁺-activated potassium channels in Jurkat T cells.  Journal of Physiology 496.3:627-637.

Aiyar J, Nguyen AN, Chandy KG, Grissmer S.  1994.  The P-region and S6 of Kv3.1 contribute to the formation of the ion conduction pathway.  Biophysical Journal 67:2261-2264.

Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, and Chandy KG.  1994.  Pharmacological characterization of five cloned voltage-gated K⁺ channels, Kv1.1, Kv1.2, Kv1.3, Kv1.5, and Kv3.1, stably expressed in mammalian cell lines.  Molecular Pharmacology 45:1227-1234.

Aldenhoff J, Grissmer S, Müller W.  1994.  Cell, calcium and psychiatry.  European Archives of Psychiatry and Clinical Neuroscience 243:213.

Aiyar J, Grissmer S, Chandy KG.  1993.  Full-length and truncated Kv1.3 K⁺ channels are modulated by 5-HT_1C receptor activation and independently by PKC.  American Journal of Physiology 265(Cell Physiol.34):C1571-C1578.

Grissmer S, Nguyen AN, Cahalan MD.  1993.  Calcium-activated potassium channels in resting and activated human T lymphocytes.  Expression levels, calcium dependence, ion selectivity, and pharmacology.  Journal of General Physiology 102:601-630.

Chandy KG, Gutman GA, Grissmer S.  1993.  Physiological role, molecular structure, and evolutionary relationships of voltage-gated potassium channels in T lymphocytes.  Seminars in The Neurosciences 5:125-134.

Grissmer S, Ghanshani S, Dethlefs B, McPherson J, Wasmuth JJ, Gutman GA, Cahalan MD, Chandy KG.  1992.  The Shaw-related Potassium-Channel Gene, Kv3.1, on Human Chromosome 11, Encodes the Type l K⁺ channel in T Cells.  Journal of Biological Chemistry 267(29):20971-20979.

Grissmer S, Lewis RS, Cahalan MD.  1992.  Ca²⁺-activated K⁺ channels in a human leucemic T-cell line.  Journal of General Physiology 99:63-87.

Cahalan MD, Chandy KG, Grissmer S.  1991.  Potassium channels in development, activation, and disease in T lymphocytes.  In:  Current Topics in Membranes.  Developmental Biology of Membrane Transport Systems, ed. Benos DJ. 39:357-394.

Grissmer S, Dethlefs B, Wasmuth JJ, Goldin AL, Gutman GA, Cahalan MD, Chandy KG.  1990.  Expression and chromosomal localization of a lymphocyte K⁺ channel gene. Proceedings of the National Academy of Sciences, USA 87:9411-9416.

Grissmer S, Hanson DC, Natoli EJ, Cahalan MD, Chandy KG.  1990.  CD4^-CD8^- T cells from mice with collagen arthritis display aberrant expression of type l K⁺ channels.  Journal of Immunology145:2105-2109.

Chandy KG, Cahalan MD, Grissmer S.  1990.  Autoimmune diseases linked to abnormal K⁺ channel expression in double-negative CD4^-CD8^- T cells.  European Journal of Immunology 20:747-751.

Grissmer S, Cahalan MD.  1989.  Divalent ion trapping inside potassium channels of human T lymphocytes.  Journal of General Physiology 93:609-630.

Grissmer S, Cahalan MD.  1989.  TEA prevents inactivation while blocking open K⁺ channels in human T lymphocytes.  Biophysical Journal 55:203-206.

Grissmer S, Cahalan MD, Chandy KG.  1988.  Abundant expression of type l K⁺ channels: a marker for lymphoproliferative diseases?  Journal of Immunology 141:1137-1142.

Grissmer S.  1986.  Properties of potassium and sodium channels in frog internode.  Journal of Physiology 381:119-134.

Grissmer S.  1984.  Effect of various cations and anions on the action of tetrodotoxin and saxitoxin on frog myelinated nerve fibres.  Pflügers Archiv European Journal of Physiology 402:353-359.

Back to our homepage!